There is increasing use of modern devices in the management of patients with type 1 diabetes (T1D). We investigated temporal trends for diabetes management and outcomes in Korean pediatric T1D patients over 10 years.
Methods:
We retrospectively collected the data from 752 participants (boys: 311, 41.4%) diagnosed with T1D and aged ≤18 years, with ≥1 year of follow-up between 2010 and 2019 in any of the seven study hospitals in Korea.
Results:
Over the 10-year study period, use of continuous glucose monitoring (CGM) increased from 1.4% to 39.3%. From 2010 to 2019, there was an increased use of multiple daily insulin injections (MDI; 63.9%–77.0%, respectively) and continuous subcutaneous insulin infusion (CSII; 2.1%–14.0%, respectively), but decreased use of conventional insulin therapy (CIT, 33.9%–9.0%, respectively). Mean glycated hemoglobin (HbA1c) decreased from 8.56% to 8.01% (P < 0.001) and was lower in younger patients, boys, and CGM users (P < 0.001). MDI and CSII users had lower mean HbA1c levels than CIT users (P = 0.003). Regarding the acute complications of T1D, CGM use was associated with lower incidences of diabetic ketoacidosis (P = 0.015); CSII users were likely to experience less severe hypoglycemia (P = 0.008).
Conclusions:
The use of CSII and CGM increased ∼7- and 30-fold, respectively, over the 10-year study period. The glycemic control of pediatric T1D patients in Korea improved from 2010 to 2019, probably because of increased use of T1D technologies.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2014; 37Suppl 1:S81–S90.
2.
ZieglerR, HeidtmannB, HilgardD, et al.: Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes, 2011; 12:11–17.
3.
AtkinsonMA, EisenbarthGS, MichelsAW: Type 1 diabetes. Lancet, 2014; 383:69–82.
4.
HummelK, McFannKK, RealsenJ, et al.: The increasing onset of type 1 diabetes in children. J Pediatr, 2012; 161:652–657.e651.
5.
KimJH, LeeCG, LeeYA, et al.: Increasing incidence of type 1 diabetes among Korean children and adolescents: analysis of data from a nationwide registry in Korea. Pediatr Diabetes, 2016; 17:519–524.
6.
LipmanTH, Levitt KatzLE, RatcliffeSJ, et al.: Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia Pediatric Diabetes Registry. Diabetes Care, 2013; 36:1597–1603.
7.
PattersonCC, DahlquistGG, GyurusE, et al.: Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet, 2009; 373:2027–2033.
8.
PattersonC, GuariguataL, DahlquistG, et al.: Diabetes in the young - a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract, 2014; 103:161–175.
9.
ChiangJL, KirkmanMS, LaffelLM, et al: Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care, 2014; 37:2034–2054.
10.
DeSalvoDJ, MillerKM, HermannJM, et al.: Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes, 2018; 19:1271–1275.
11.
Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr, 1994; 125:177–188.
12.
SherrJL, TauschmannM, BattelinoT, et al.: ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies. Pediatr Diabetes, 2018; 19Suppl 27:302–325.
13.
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: standards of Medical Care in Diabetes-2021. Diabetes Care, 2021; 44(Suppl 1):S15–S33.
14.
HanleyJA, Lippman-HandA: If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA, 1983; 249:1743–1745.
15.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2020.
16.
BohnB, KernerW, SeufertJ, et al.: Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Res Clin Pract, 2016; 115:31–38.
17.
van den BoomL, KargesB, AuzanneauM, et al.: Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care, 2019; 42:2050–2056.
18.
BohnB, KargesB, VogelC, et al.: 20 years of pediatric benchmarking in Germany and Austria: age-dependent analysis of longitudinal follow-up in 63,967 children and adolescents with type 1 diabetes. PLoS One, 2016; 11:e0160971.
19.
MillerKM, FosterNC, BeckRW, et al.: Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care, 2015; 38:971–978.
20.
FosterNC, BeckRW, MillerKM, et al.: State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther, 2019; 21:66–72.
21.
KimJH: Current status of continuous glucose monitoring among Korean children and adolescents with type 1 diabetes mellitus. Ann Pediatr Endocrinol Metab, 2020; 25:145–151.
22.
SherrJL, HermannJM, CampbellF, et al.: Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia, 2016; 59:87–91.
23.
YamamotoY, KikuchiT, UrakamiT, et al.: Status and trends in the use of insulin analogs, insulin delivery systems and their association with glycemic control: comparison of the two consecutive recent cohorts of Japanese children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab, 2019; 32:1–9.
24.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring StudyGroup, BeckRW, HirschIB, et al.: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care, 2009; 32:1378–1383.
25.
MulinacciG, AlonsoGT, Snell-BergeonJK, ShahVN: Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther, 2019; 21:6–10.
26.
FosterNC, MillerKM, TamborlaneWV, et al.: Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care, 2016; 39:e81–e82.
27.
NwosuBU, YeasminS, AyyoubS, et al.: Continuous glucose monitoring reduces pubertal hyperglycemia of type 1 diabetes. J Pediatr Endocrinol Metab, 2020; 33:865–872.
28.
American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes-2020. Diabetes Care, 2020; 43(Suppl 1):S77–S88.
29.
BeckRW, BergenstalRM, LaffelLM, PickupJC: Advances in technology for management of type 1 diabetes. Lancet, 2019; 394:1265–1273.
30.
BattelinoT, DanneT, BergenstalRM, et al.: Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care, 2019; 42:1593–1603.
31.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring StudyGroup, TamborlaneWV, BeckRW, et al.: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med, 2008; 359:1464–1476.
32.
CapponG, VettorettiM, SparacinoG, FacchinettiA: Continuous glucose monitoring sensors for diabetes management: a review of technologies and applications. Diabetes Metab J, 2019; 43:383–397.
33.
PalaL, DicembriniI, MannucciE: Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol, 2019; 56:973–980.
34.
TauschmannM, HovorkaR: Technology in the management of type 1 diabetes mellitus—current status and future prospects. Nat Rev Endocrinol, 2018; 14:464–475.
35.
YehHC, BrownTT, MaruthurN, et al.: Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med, 2012; 157:336–347.
36.
PickupJC, SuttonAJ: Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med, 2008; 25:765–774.
37.
MonamiM, LamannaC, MarchionniN, MannucciE: Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol, 2010; 47Suppl 1:77–81.
38.
FatourechiMM, KudvaYC, MuradMH, et al.: Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab, 2009; 94:729–740.
39.
JeitlerK, HorvathK, BergholdA, et al.: Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia, 2008; 51:941–951.
40.
PankowskaE, BlazikM, DziechciarzP, et al.: Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes, 2009; 10:52–58.
41.
JoubertM, MoreraJ, VicenteA, et al.: Cross-sectional survey and retrospective analysis of a large cohort of adults with type 1 diabetes with long-term continuous subcutaneous insulin infusion treatment. J Diabetes Sci Technol, 2014; 8:1005–1010.
42.
OrrCJ, HopmanW, YenJL, HouldenRL: Long-term efficacy of insulin pump therapy on glycemic control in adults with type 1 diabetes mellitus. Diabetes Technol Ther, 2015; 17:49–54.
43.
JohnsonSR, CooperMN, JonesTW, DavisEA: Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia, 2013; 56:2392–2400.
44.
SteineckI, CederholmJ, EliassonB, et al.: Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ, 2015; 350:h3234.
45.
KargesB, SchwandtA, HeidtmannB, et al.: Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA, 2017; 318:1358–1366.
46.
LeeYJ, LeeYA, KimJH, et al.: The durability and effectiveness of sensor-augmented insulin pump therapy in pediatric and young adult patients with type 1 diabetes. Ann Pediatr Endocrinol Metab, 2020; 25:248–255.
47.
MissoML, EgbertsKJ, PageM, et al.: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev, 2010:CD005103.
48.
Fazeli FarsaniS, BrodoviczK, SoleymanlouN, et al.: Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open, 2017; 7:e016587.
49.
EggerM, Davey SmithG, StettlerC, DiemP: Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med, 1997; 14:919–928.
50.
Tubiana-RufiN, de LonlayP, BlochJ, CzernichowP: [Remission of severe hypoglycemic incidents in young diabetic children treated with subcutaneous infusion]. Arch Pediatr, 1996; 3:969–976.
51.
Cardona-HernandezR, SchwandtA, AlkandariH, et al.: Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the international pediatric registry SWEET. Diabetes Care, 2021; 44:1176–1184.
52.
MecklenburgRS, BensonEA, BensonJWJr, et al.: Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA, 1984; 252:3265–3269.
53.
HanasR, LindgrenF, LindbladB: A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes, 2009; 10:33–37.
54.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring StudyG, BeckRW, HirschIB, et al.: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care, 2009; 32:1378–1383.
55.
BuckinghamB, BlockJ, BurdickJ, et al.: Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther, 2005; 7:440–447.
56.
HamiltonJ, DanemanD: Deteriorating diabetes control during adolescence: physiological or psychosocial?. J Pediatr Endocrinol Metab, 2002; 15:115–126.
57.
MoranA, JacobsDRJr., SteinbergerJ, et al.: Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes, 1999; 48:2039–2044.
58.
UrakamiT, SuzukiJ, YoshidaA, et al.: Association between sex, age, insulin regimens and glycemic control in children and adolescents with type 1 diabetes. Clin Pediatr Endocrinol, 2010; 19:1–6.
59.
AmielSA, SherwinRS, SimonsonDC, et al.: Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med, 1986; 315:215–219.
60.
MartinD, ElieC, DossierC, et al.: Diabetes knowledge in adolescents with type 1 diabetes and their parents and glycemic control. Pediatr Diabetes, 2017; 18:559–565.
61.
GerstlEM, RablW, RosenbauerJ, et al.: Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr, 2008; 167:447–453.
62.
GoblCS, BozkurtL, LueckJ, et al.: Sex-specific differences in long-term glycemic control and cardiometabolic parameters in patients with type 1 diabetes treated at a tertiary care centre: gender aspects in type 1 diabetes. Wien Klin Wochenschr, 2012; 124:742–749.
63.
MaiorinoMI, BellastellaG, CascianoO, et al.: Gender-differences in glycemic control and diabetes related factors in young adults with type 1 diabetes: results from the METRO study. Endocrine, 2018; 61:240–247.
64.
SherryNA, TsaiEB, HeroldKC: Natural history of beta-cell function in type 1 diabetes. Diabetes, 2005; 54Suppl 2:S32–S39.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
